UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005418
Receipt number R000006027
Scientific Title Multicenter retrospective study for trasient abnormal myelopoiesis (JPLSG TAM-10)
Date of disclosure of the study information 2011/04/15
Last modified on 2021/04/16 11:48:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multicenter retrospective study for trasient abnormal myelopoiesis (JPLSG TAM-10)

Acronym

JPLSG TAM-10

Scientific Title

Multicenter retrospective study for trasient abnormal myelopoiesis (JPLSG TAM-10)

Scientific Title:Acronym

JPLSG TAM-10

Region

Japan


Condition

Condition

Transient abnormal myelopoiesis

Classification by specialty

Pediatrics

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The aim of this study is to clarify the short term and long term prognosis of patients with transient abnormal myelopoiesis by multicenter prospective observational study.

Basic objectives2

Bio-equivalence

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Event free survival

Key secondary outcomes

Overall survival
Proportion of patients who received chemotherapy
Percentage of adverse events
Cumulative incidence of progression to acute leukemia


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 months-old <=

Age-upper limit

3 months-old >

Gender

Male and Female

Key inclusion criteria

Inclusion criteria is as follows:
1) Patient is diagnosised as Down syndrome or mosaic Down syndrome. But patients without Down syndrome who has megakaryocytic blast with GATA1 mutation and somatic trisomy 21 are including to this study.
2) Patient is diagnosed with transient abnormal myelopoiesis under 90 das after birth.
3) Registration should be done within 30 days after diagnosis.
4) Diagnosed day should be after the opening day of this study.
5) Written informed concent by patient's guardian should be obtained.

Key exclusion criteria

none

Target sample size

75


Research contact person

Name of lead principal investigator

1st name Akira
Middle name
Last name Kikuchi

Organization

Teikyo University School of Medicine

Division name

Department of Pediatrics

Zip code

173-8606

Address

2-11-1 Kaga, Itabashi-ku, Tokyo

TEL

03-3964-1211

Email

hideki-muramatsu@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name Emiko
Middle name
Last name Nishioka

Organization

JPLSG

Division name

TAM committee

Zip code

460-0001

Address

3-1-1, San-nomaru, Naka-ku, Nagoya, Japan

TEL

052-228-7159

Homepage URL

http://www.jplsg.jp/10siken_sankasisetu/fre_shiken_sannkasisetu.htm

Email

officej2@jplsg.jp


Sponsor or person

Institute

JPLSG

Institute

Department

Personal name



Funding Source

Organization

Transient abnormal myelopoiesis with Down syndrome research group

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagoya University Hospital

Address

65, Tsurumai-cho, showa-ku, Nagoya

Tel

0527412111

Email

hideki-muramatsu@med.nagoya-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 04 Month 15 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

https://www.nature.com/articles/s41375-021-01171-y

Number of participants that the trial has enrolled

167

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2011 Year 02 Month 07 Day

Date of IRB

2011 Year 02 Month 07 Day

Anticipated trial start date

2011 Year 04 Month 01 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

We will analyzed the short term and long term outcome of patients with transient abnormal myelopoiesis.


Management information

Registered date

2011 Year 04 Month 09 Day

Last modified on

2021 Year 04 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006027


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name